marketcaparena
Search

    ACH

    ACCENDRA HEALTH INC/VA/

    Company overview

    Market capitalization
    $49.99M
    Employees
    6,500
    Latest publication
    2026-09-29
    About ACCENDRA HEALTH INC/VA/

    Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines including ostomy, wound care and negative pressure wound therapy, urology, incontinence, and other products and services. It serves patients and home health agencies. The company was formerly known as Owens & Minor, Inc. and changed its name to Accendra Health, Inc. in December 2025. Accendra Health, Inc. was founded in 1882 and is based in Glen Allen, Virginia.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue613,234,000USD627,780,000USD708,967,000USD697,264,000USD681,917,000USD2,632,048,000USD2,696,073,000USD686,846,000USD
    Cost Of Revenue349,827,000USD382,605,000USD418,675,000USD407,472,000USD384,831,000USD2,106,035,000USD2,116,307,000USD355,075,000USD
    Gross Profit263,407,000USD245,175,000USD290,292,000USD289,792,000USD297,086,000USD526,013,000USD579,766,000USD331,771,000USD
    Selling General Administrative243,560,000USD255,226,000USD271,499,000USD265,838,000USD267,853,000USD462,352,000USD101,374,000USD272,322,000USD
    Total Operating Expenses298,557,000USD251,309,000USD268,271,000USD260,668,000USD247,816,000USD525,889,000USD841,733,000USD300,692,000USD
    Operating Income-35,150,000USD-6,134,000USD22,021,000USD29,124,000USD49,270,000USD124,000USD-261,967,000USD31,079,000USD
    Total Other Income Expense Net-52,478,000USD-10,111,999USD-29,992,000USD-32,759,000USD-134,219,000USD-35,198,000USD-37,684,000USD-30,121,000USD
    Interest Expense34,539,000USD32,869,999USD28,673,000USD29,975,000USD45,228,000USD33,959,000USD35,696,000USD36,554,000USD
    Income Before Tax-87,628,000USD-16,245,999USD-7,971,000USD-3,635,000USD-84,949,000USD-35,074,000USD-299,651,000USD958,000USD
    Income Tax Expense1,442,000USD-9,778,000USD1,472,000USD1,972,000USD-1,127,000USD-10,092,000USD-3,535,000USD-303,000USD
    Net Income-89,070,000USD-6,468,000USD-56,326,000USD-150,276,000USD-869,058,000USD-24,982,000USD-296,116,000USD-12,770,000USD
    Unclassified Operating Expenses—-3,917,000USD-3,228,000USD-5,170,000USD-20,037,000USD63,537,000USD740,359,000USD28,370,000USD
    Net Interest Income—-32,348,000USD-27,931,000USD-29,029,000USD-26,009,000USD-33,959,000USD-35,696,000USD-28,953,000USD
    Tax Provision—-9,778,000USD1,472,000USD1,972,000USD-1,127,000USD-10,092,000USD-3,535,000USD-303,000USD
    Net Income From Continuing Ops—-6,468,000USD-9,443,000USD-5,607,000USD-83,822,000USD-24,982,000USD-296,116,000USD1,261,000USD
    Ebit—-6,134,000USD22,021,000USD29,124,000USD49,270,000USD-1,115,000USD-263,955,000USD29,911,000USD
    Ebitda—55,608,000USD86,557,000USD93,223,000USD108,669,000USD60,038,000USD-198,768,000USD91,525,000USD
    Depreciation And Amortization—61,742,000USD64,536,000USD64,099,000USD59,399,000USD61,153,000USD65,187,000USD61,614,000USD
    Reconciled Depreciation—61,742,000USD29,873,000USD64,099,000USD59,399,000USD61,153,000USD65,187,000USD61,614,000USD
    Interest Income——27,931,000USD29,029,000USD26,009,000USD33,959,000USD——
    Net Income Applicable To Common Shares——-56,326,000USD-150,276,000USD-869,058,000USD-24,982,000USD——
    Source0001104659-26-093177DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue2,762,032,000USD10,700,883,000USD10,333,967,000USD9,955,475,000USD9,785,315,000USD8,480,177,000USD9,210,939,000USD9,418,192,000USD
    Cost Of Revenue1,560,427,000USD8,481,728,000USD8,208,806,000USD8,129,124,000USD8,272,086,000USD7,199,343,000USD8,082,448,000USD8,347,666,000USD
    Gross Profit1,201,605,000USD2,219,155,000USD2,125,161,000USD1,826,351,000USD1,513,229,000USD1,280,834,000USD1,128,491,000USD1,070,526,000USD
    Selling General Administrative1,067,560,000USD1,909,773,150USD1,813,559,000USD1,554,821,000USD1,077,064,000USD653,665,000USD602,665,999USD1,261,748,000USD
    Unclassified Operating Expenses-16,112,000USD517,133,000USD207,076,450USD128,600,590USD55,580,590USD34,051,000USD30,674,001USD161,124,000USD
    Total Operating Expenses1,051,448,000USD2,426,924,000USD2,020,653,000USD1,683,438,000USD1,144,756,000USD1,076,716,000USD1,055,340,000USD1,422,872,000USD
    Operating Income150,157,000USD-207,769,000USD104,508,000USD142,913,000USD368,473,000USD204,118,000USD73,151,000USD-352,346,000USD
    Interest Income107,183,000USD143,804,000USD157,915,000USD128,891,000USD————
    Interest Expense129,199,000USD143,804,000USD157,915,000USD128,891,000USD48,090,000USD83,398,000USD98,113,000USD70,983,000USD
    Net Interest Income-107,183,000USD-143,804,000USD-157,915,000USD-128,891,000USD-48,090,000USD———
    Income Before Tax-101,953,000USD-357,357,000USD-54,726,000USD10,891,000USD276,754,000USD109,908,000USD-28,719,000USD-427,094,000USD
    Income Tax Expense729,000USD5,329,000USD-13,425,000USD-11,498,000USD55,165,000USD21,834,000USD-6,135,000USD32,429,000USD
    Tax Provision729,000USD5,329,000USD-13,425,000USD-11,498,000USD55,165,000USD———
    Net Income-1,100,642,000USD-362,686,000USD-41,301,000USD22,389,000USD221,589,000USD29,871,000USD-62,371,000USD-437,012,000USD
    Net Income From Continuing Ops-102,682,000USD-362,686,000USD-41,301,000USD22,389,000USD221,589,000USD———
    Ebit150,157,000USD-213,553,000USD103,189,000USD139,782,000USD324,844,000USD240,278,000USD99,278,000USD-356,111,000USD
    Ebitda364,681,000USD51,222,000USD390,566,000USD368,449,000USD415,465,000USD323,414,000USD186,724,000USD-272,712,000USD
    Depreciation And Amortization214,524,000USD264,775,000USD287,377,000USD228,667,000USD90,621,000USD83,136,000USD87,446,000USD83,399,000USD
    Reconciled Depreciation214,524,000USD264,775,000USD287,377,000USD228,667,000USD90,621,000USD———
    Total Other Income Expense Net-252,110,000USD-149,588,000USD-159,234,000USD-132,022,000USD-91,719,000USD-94,210,000USD-101,870,000USD-74,748,000USD
    Net Income Applicable To Common Shares-1,100,642,000USD-362,686,000USD-41,301,000USD22,389,000USD————
    Selling And Marketing Expenses—17,850USD17,550USD16,410USD11,410USD389,000,000USD422,000,000USD—
    Research Development————12,100,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets2,107,412,000USD2,415,982,000USD2,451,761,000USD4,036,226,000USD4,154,545,000USD4,856,424,000USD4,656,156,000USD5,081,282,000USD
    Cash And Equivalents7,651,000USD—281,989,000USD32,837,000USD38,258,000USD59,436,000USD——
    Total Current Assets271,449,000USD588,500,000USD547,871,000USD2,131,673,000USD2,298,513,000USD2,206,198,000USD2,021,017,000USD2,116,538,000USD
    Other Current Assets70,371,000USD82,632,000USD95,540,000USD1,832,258,000USD1,994,649,000USD158,048,000USD149,515,000USD166,967,000USD
    Other Non Current Assets224,142,000USD———————
    Total Liabilities2,658,350,000USD———————
    Total Current Liabilities666,216,000USD1,203,104,000USD947,075,000USD2,465,967,000USD2,674,523,000USD1,960,215,000USD1,873,739,000USD1,934,166,000USD
    Other Current Liabilities271,586,000USD———————
    Other Non Current Liabilities210,836,000USD———————
    Total Stockholder Equity-550,938,000USD-464,765,000USD-460,978,000USD-429,507,000USD-281,010,000USD570,979,000USD565,226,000USD874,592,000USD
    Total Equity Including Noncontrolling Interest-550,938,000USD———————
    Short Long Term Debt0USD581,250,000USD250,000,000USD280,000,000USD383,000,000USD47,500,000USD40,000,000USD42,626,000USD
    Long Term Debt1,718,063,000USD1,521,941,000USD1,799,876,000USD1,835,261,000USD1,594,745,000USD1,890,929,000USD1,799,115,000USD1,842,348,000USD
    Inventory73,345,000USD65,285,000USD74,435,000USD63,847,000USD69,227,000USD1,408,539,000USD1,131,879,000USD1,242,453,000USD
    Property Plant Equipment Net305,674,000USD329,699,000USD365,260,000USD378,822,000USD379,489,000USD903,443,000USD864,974,000USD856,010,000USD
    Goodwill1,228,140,000USD———————
    Intangible Assets78,007,000USD107,236,000USD136,465,000USD165,694,000USD194,924,000USD283,086,000USD298,726,000USD313,284,000USD
    Accounts Payable352,798,000USD374,824,000USD363,565,000USD339,728,000USD357,037,000USD1,380,736,000USD1,251,964,000USD1,338,021,000USD
    Short Term Debt38,397,000USD581,250,000USD293,272,000USD280,000,000USD426,704,000USD49,900,000USD50,749,000USD48,026,000USD
    Common Stock153,809,000USD153,167,000USD152,777,000USD154,598,000USD154,393,000USD154,439,000USD154,398,000USD154,123,000USD
    Retained Earnings-1,175,290,000USD-1,086,220,000USD-1,079,752,000USD-1,022,161,000USD-871,885,000USD1,020,000USD6,021,000USD302,138,000USD
    Accumulated Other Comprehensive Income-1,051,000USD-798,000USD-885,000USD-30,413,000USD-30,219,000USD-44,211,000USD-49,343,999USD-27,418,000USD
    Total Liab—2,880,747,000USD2,912,739,000USD4,465,733,000USD4,435,555,000USD4,285,445,000USD4,090,930,000USD4,206,690,000USD
    Other Current Liab—247,030,000USD290,238,000USD1,846,239,000USD1,890,782,000USD529,579,000USD571,026,000USD548,119,000USD
    Capital Stock—153,167,000USD152,777,000USD154,598,000USD154,393,000USD154,439,000USD154,398,000USD154,123,000USD
    Good Will—1,228,140,000USD1,228,140,000USD1,228,140,000USD1,228,140,000USD1,331,931,000USD1,331,281,000USD1,642,196,000USD
    Cash—336,880,000USD281,989,000USD32,837,000USD38,258,000USD59,436,000USD49,382,000USD45,454,000USD
    Cash And Short Term Investments—336,880,000USD281,989,000USD32,837,000USD38,258,000USD59,436,000USD49,382,000USD45,454,000USD
    Net Debt—1,833,777,000USD1,951,793,000USD2,163,776,000USD2,064,173,000USD2,212,058,000USD2,090,426,000USD2,127,563,000USD
    Short Long Term Debt Total—2,170,657,000USD2,233,782,000USD2,196,613,000USD2,102,431,000USD2,271,494,000USD2,139,808,000USD2,173,017,000USD
    Net Receivables—103,703,000USD95,907,000USD202,731,000USD196,379,000USD580,175,000USD690,241,000USD661,664,000USD
    Property Plant Equipment Gross—510,638,000USD572,855,000USD581,809,000USD573,708,000USD1,485,729,000USD1,430,093,000USD1,426,043,000USD
    Common Stock Shares Outstanding—76,699,000shares76,699,000shares77,288,000shares76,935,000shares77,272,000shares77,169,000shares77,090,000shares
    Non Current Assets Total—1,827,482,000USD1,903,889,999USD1,904,553,000USD1,856,032,000USD2,648,226,000USD2,633,139,000USD2,964,744,000USD
    Non Current Liabilities Total—1,677,642,999USD1,965,664,000USD1,999,766,000USD1,761,032,000USD2,325,230,000USD2,217,191,000USD2,272,524,000USD
    Non Current Liabilities Other—88,236,000USD95,471,000USD83,153,000USD84,960,000USD87,329,000USD100,127,000USD116,483,000USD
    Non Currrent Assets Other—162,407,000USD172,686,999USD129,896,000USD50,727,000USD125,840,000USD134,045,000USD107,747,000USD
    Net Working Capital—-614,604,000USD-399,204,000USD-334,294,000USD-376,010,000USD245,983,000USD147,278,000USD182,372,000USD
    Unclassified Current Liabilities—-581,250,000USD-250,000,000USD-280,000,000USD-383,000,000USD-47,500,000USD-40,000,000USD-42,626,000USD
    Unclassified Non Current Liabilities—67,465,999USD70,317,000USD81,352,000USD81,327,000USD346,972,000USD317,949,000USD313,693,000USD
    Unclassified Equity—315,919,000USD314,105,000USD313,871,000USD312,308,000USD305,292,000USD299,752,999USD291,626,000USD
    Other Assets——174,025,000USD131,897,000USD53,479,000USD2,000,000USD2,000,000USD—
    Unclassified Non Current Assets——-172,687,000USD-129,896,000USD-50,727,000USD——45,507,000USD
    Source0001104659-26-093177DeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets2,451,761,000USD4,656,156,000USD5,093,322,000USD5,386,283,000USD3,536,551,000USD3,335,639,000USD3,643,084,000USD3,773,788,000USD
    Intangible Assets136,465,000USD296,726,000USD361,835,000USD483,742,000USD243,745,000USD281,351,000USD285,018,000USD321,764,000USD
    Other Current Assets95,540,000USD149,515,000USD150,890,000USD128,636,000USD88,564,000USD83,137,999USD519,355,000USD425,480,000USD
    Total Liab2,912,739,000USD4,090,930,000USD4,169,156,000USD4,440,679,000USD2,598,050,000USD2,623,585,000USD3,180,930,000USD3,255,369,000USD
    Total Stockholder Equity-460,978,000USD565,226,000USD924,166,000USD945,604,000USD938,501,000USD712,054,000USD462,154,000USD518,419,000USD
    Other Current Liab290,238,000USD576,575,000USD311,036,000USD324,341,000USD298,208,000USD311,044,000USD484,769,000USD435,502,000USD
    Common Stock152,777,000USD154,398,000USD153,092,000USD152,557,000USD150,865,000USD146,944,000USD125,686,000USD124,588,000USD
    Capital Stock152,777,000USD154,398,000USD153,092,000USD152,557,000USD150,865,000USD———
    Retained Earnings-1,079,752,000USD6,021,000USD368,707,000USD410,008,000USD387,619,000USD167,022,000USD137,774,000USD200,670,000USD
    Good Will1,228,140,000USD1,331,281,000USD1,638,846,000USD1,636,705,000USD390,185,000USD394,086,000USD393,181,000USD414,122,000USD
    Other Assets174,025,000USD2,000,000USD149,346,000USD150,417,000USD————
    Cash281,989,000USD49,382,000USD243,037,000USD69,467,000USD55,712,000USD118,184,000USD67,030,000USD66,308,000USD
    Cash And Equivalents281,989,000USD49,382,000USD243,037,000USD69,467,000USD————
    Cash And Short Term Investments281,989,000USD49,382,000USD243,037,000USD69,467,000USD55,712,000USD118,184,000USD67,030,000USD66,308,000USD
    Total Current Assets547,871,000USD2,021,017,000USD2,102,790,000USD2,295,185,000USD2,321,812,000USD2,135,864,999USD2,407,283,000USD2,538,578,000USD
    Total Current Liabilities947,075,000USD1,873,739,000USD1,891,885,000USD1,566,466,000USD1,344,021,000USD1,345,727,000USD1,416,159,000USD1,472,011,000USD
    Net Debt1,951,793,000USD2,090,426,000USD2,162,559,000USD2,723,681,000USD1,097,923,000USD1,022,263,000USD1,641,270,000USD1,584,274,000USD
    Short Term Debt293,272,000USD45,200,000USD292,569,000USD94,711,000USD43,854,000USD34,497,000USD82,805,000USD28,688,000USD
    Short Long Term Debt250,000,000USD40,000,000USD206,904,000USD17,906,000USD————
    Short Long Term Debt Total2,233,782,000USD2,139,808,000USD2,405,596,000USD2,793,148,000USD1,153,635,000USD1,140,447,000USD1,708,300,000USD1,650,582,000USD
    Long Term Debt1,799,876,000USD1,799,115,000USD1,890,598,000USD2,482,968,000USD947,540,000USD———
    Net Receivables95,907,000USD690,241,000USD598,257,000USD763,497,000USD681,564,000USD700,792,000USD674,706,000USD756,687,000USD
    Inventory74,435,000USD1,131,879,000USD1,110,606,000USD1,333,585,000USD1,495,972,000USD1,233,751,000USD1,146,192,000USD1,290,103,000USD
    Accounts Payable363,565,000USD1,251,964,000USD1,171,882,000USD1,147,414,000USD1,001,959,000USD1,000,186,000USD808,035,000USD1,065,197,000USD
    Property Plant Equipment Net365,260,000USD864,974,000USD840,505,000USD858,934,000USD511,241,000USD460,417,000USD457,646,000USD386,723,000USD
    Property Plant Equipment Gross572,855,000USD1,430,093,000USD1,386,902,000USD1,309,220,000USD845,741,000USD———
    Accumulated Other Comprehensive Income-885,000USD-49,344,000USD-31,818,000USD-35,854,999USD-40,591,000USD-38,509,000USD-52,707,000USD-45,612,000USD
    Common Stock Shares Outstanding76,897,000shares76,741,000shares75,785,000shares76,217,000shares75,486,000shares63,512,000shares60,574,000shares60,014,000shares
    Non Current Assets Total1,903,889,999USD2,633,139,000USD2,990,532,000USD3,091,098,000USD1,214,739,000USD1,199,774,000USD1,235,801,000USD1,235,210,000USD
    Non Current Liabilities Total1,965,664,000USD2,217,191,000USD2,277,271,000USD2,874,213,000USD1,254,029,000USD1,277,858,000USD1,764,771,000USD1,783,358,000USD
    Non Current Liabilities Other95,471,000USD100,127,000USD122,592,000USD114,943,000USD108,938,000USD———
    Non Currrent Assets Other172,686,999USD134,045,000USD149,346,000USD96,256,000USD53,245,000USD47,598,000USD99,956,000USD112,601,000USD
    Net Working Capital-399,204,000USD147,278,000USD210,905,000USD728,719,000USD977,791,000USD———
    Unclassified Non Current Assets-172,687,000USD—-149,346,000USD-134,956,000USD16,323,000USD16,322,000USD——
    Unclassified Current Liabilities-250,000,000USD-40,000,000USD-206,904,000USD-17,906,000USD———-57,376,000USD
    Unclassified Non Current Liabilities70,317,000USD317,949,000USD264,081,000USD276,302,000USD197,551,000USD1,277,858,000USD1,764,771,000USD1,783,358,000USD
    Unclassified Equity314,105,000USD299,753,000USD281,093,000USD266,336,999USD289,743,000USD436,597,000USD251,401,000USD238,773,000USD
    Current Deferred Revenue——116,398,000USD———40,550,000USD-28,688,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation127,442,000USD
    Stock Based Compensation7,094,000USD
    Deferred Income Tax-45,489,000USD
    Other Non Cash Items-6,767,000USD
    Change To Inventory1,090,000USD
    Change In Working Capital1,090,000USD
    Operating Cash Flow-76,083,000USD
    Capital Expenditures-89,232,000USD
    Other Investing Activities-2,100,000USD
    Unclassified Investing Cash Flow114,012,000USD
    Investing Cash Flow22,680,000USD
    Net Debt Issuance-1,237,315,000USD
    Other Financing Activities-603,000USD
    Unclassified Financing Cash Flow1,017,024,000USD
    Financing Cash Flow-220,894,000USD
    Effect Of Forex Changes On Cash-41,000USD
    Change In Cash-274,338,000USD
    End Cash Flow7,651,000USD
    Source0001104659-26-093177DeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-6,468,000USD941,634,000USD-150,276,000USD-83,822,000USD-24,982,000USD-296,116,000USD-12,771,000USD-31,913,000USD
    Depreciation61,742,000USD29,873,000USD64,099,000USD13,918,000USD61,153,000USD65,187,000USD61,614,000USD63,879,000USD
    Stock Based Compensation3,090,000USD-4,457,000USD2,341,000USD4,861,000USD6,928,000USD7,555,000USD5,680,000USD6,735,000USD
    Other Non Cash Items-55,387,000USD-1,144,241,000USD103,975,000USD10,023,000USD9,859,000USD308,007,000USD-4,127,000USD-6,583,000USD
    Change To Account Receivables-7,796,000USD10,863,000USD-30,375,000USD30,262,000USD111,613,000USD-35,201,000USD7,231,000USD6,702,000USD
    Change To Inventory9,150,000USD139,497,000USD9,225,000USD119,013,000USD-274,589,000USD106,205,000USD-9,356,000USD-87,665,000USD
    Change In Working Capital-55,625,000USD209,502,000USD-151,205,000USD93,757,000USD-81,784,000USD-2,636,000USD-16,999,000USD89,401,000USD
    Total Cash From Operating Activities-50,077,000USD68,186,000USD-172,520,000USD37,610,000USD-35,066,000USD71,001,000USD27,307,000USD116,149,000USD
    Capital Expenditures71,997,000USD-9,285,000USD-57,829,000USD-67,879,000USD-64,674,000USD-62,834,000USD-61,518,000USD-45,800,000USD
    Free Cash Flow21,920,000USD58,901,000USD-230,349,000USD-30,269,000USD-99,740,000USD8,167,000USD-34,211,000USD70,349,000USD
    Total Cashflows From Investing Activities53,925,000USD285,004,000USD-39,464,000USD-52,917,000USD-48,200,000USD-52,304,000USD-27,189,000USD-35,170,000USD
    Net Borrowings51,500,000USD-67,200,000USD135,700,000USD37,500,000USD97,500,000USD-32,750,000USD-199,072,000USD—
    Total Cash From Financing Activities51,084,000USD-117,496,000USD181,097,000USD31,699,000USD92,778,000USD-43,096,000USD-199,587,000USD-78,240,000USD
    Sale Purchase Of Stock0USD-3,523,000USD-6,656,000USD-5,153,000USD-1,503,000USD———
    Change In Cash54,891,000USD235,823,000USD-30,921,000USD-21,178,000USD10,054,000USD-25,708,000USD-198,379,000USD2,675,000USD
    Begin Period Cash Flow281,989,000USD46,166,000USD77,087,000USD59,436,000USD49,382,000USD75,090,000USD273,469,000USD270,794,000USD
    End Period Cash Flow336,880,000USD281,989,000USD46,166,000USD38,258,000USD59,436,000USD49,382,000USD75,090,000USD273,469,000USD
    Other Cashflows From Investing Activities-18,072,000USD298,137,000USD14,783,000USD-52,917,000USD7,497,000USD10,530,000USD30,463,000USD-6,858,000USD
    Other Cashflows From Financing Activities-416,000USD-46,773,000USD45,397,000USD-648,000USD-3,219,000USD-10,346,000USD-515,000USD-4,790,000USD
    Unclassified Operating Cash Flow2,571,000USD35,875,000USD-41,454,000USD-1,127,000USD-6,240,000USD-10,996,000USD-6,090,000USD-5,370,000USD
    Unclassified Investing Cash Flow—-3,848,000USD3,582,000USD67,879,000USD8,977,000USD—3,866,000USD17,488,000USD
    Unclassified Financing Cash Flow——6,656,000USD————-73,450,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-102,682,000USD-362,686,000USD-41,301,000USD22,389,000USD221,589,000USD29,871,000USD-62,371,000USD-437,012,000USD
    Depreciation95,832,000USD264,775,000USD287,377,000USD228,667,000USD90,621,000USD93,336,000USD116,678,000USD101,927,000USD
    Stock Based Compensation12,001,000USD26,836,000USD23,218,000USD20,993,000USD25,016,000USD20,010,000USD15,803,000USD16,376,000USD
    Other Non Cash Items-181,148,000USD284,123,000USD-27,222,000USD-10,450,000USD78,087,000USD101,896,000USD52,760,000USD455,086,000USD
    Change To Account Receivables122,363,000USD-94,550,000USD166,581,000USD1,101,000USD-2,201,000USD-34,818,000USD63,526,000USD11,106,000USD
    Change To Inventory-6,854,000USD-26,228,000USD224,338,000USD166,559,000USD-263,439,000USD-85,154,000USD127,921,000USD-65,451,000USD
    Change In Working Capital74,207,000USD-25,438,000USD522,286,000USD89,768,000USD-261,400,000USD78,546,000USD60,617,000USD14,230,000USD
    Total Cash From Operating Activities-101,790,000USD161,495,000USD740,710,000USD325,006,000USD124,177,000USD339,223,000USD166,085,000USD115,589,000USD
    Capital Expenditures-190,956,000USD-228,162,000USD-207,892,000USD-166,582,000USD-49,690,000USD-59,193,000USD-52,228,000USD-65,685,000USD
    Free Cash Flow-292,746,000USD-66,667,000USD532,818,000USD158,424,000USD74,487,000USD280,030,000USD113,857,000USD49,904,000USD
    Total Cashflows From Investing Activities144,423,000USD-116,533,000USD-137,254,000USD-1,804,476,000USD-53,630,000USD80,073,000USD-51,897,000USD-815,829,000USD
    Net Borrowings203,500,000USD-244,197,000USD-416,693,000USD1,582,500,000USD-81,440,000USD———
    Total Cash From Financing Activities188,078,000USD-267,603,000USD-417,330,000USD1,497,105,000USD-129,478,000USD-379,386,000USD-130,197,000USD701,071,000USD
    Sale Purchase Of Stock-10,179,000USD0USD0USD0USD————
    Change In Cash232,607,000USD-223,542,000USD186,739,000USD14,150,000USD-62,471,000USD49,819,000USD-18,680,000USD-1,155,000USD
    Begin Period Cash Flow49,382,000USD272,924,000USD86,185,000USD72,035,000USD134,506,000USD84,687,000USD103,367,000USD104,522,000USD
    End Period Cash Flow281,989,000USD49,382,000USD272,924,000USD86,185,000USD72,035,000USD134,506,000USD84,687,000USD103,367,000USD
    Other Cashflows From Investing Activities144,423,000USD94,332,000USD53,616,000USD46,713,000USD39,433,000USD-2,503,000USD-9,478,000USD1,690,000USD
    Other Cashflows From Financing Activities-5,243,000USD-23,406,000USD-637,000USD-85,395,000USD-33,395,000USD-26,858,000USD-7,179,000USD-35,729,000USD
    Unclassified Investing Cash Flow190,956,000USD17,297,000USD17,022,000USD-1,684,607,000USD-43,373,000USD141,769,000USD9,809,000USD-751,834,000USD
    Unclassified Operating Cash Flow—-26,115,000USD-23,648,000USD-26,361,000USD-29,736,000USD15,564,000USD-17,402,000USD-35,018,000USD
    Dividends Paid——0USD0USD-731,000USD-648,000USD-5,226,000USD-48,200,000USD
    Issuance Of Capital Stock———0USD0USD———
    Unclassified Financing Cash Flow————-13,912,000USD-351,880,000USD-117,792,000USD785,000,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    Days Sales Outstanding

    Period endPeriodValueUnitSource
    2026-06-30instant17.8daysDisclosure

    Days Sales Outstanding excluding Receivables Sale Program

    Period endPeriodValueUnitSource
    2026-06-30instant37.1daysDisclosure

    Patient Service Equipment Capital Expenditures

    Period endPeriodValueUnitSource
    2026-06-30quarterly-43,796USD thousandsDisclosure

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductDiabetes Product185,786,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductHome Respiratory Therapy Product97,179,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductOstomy51,336,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductProduct And Service Other57,365,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductSleep Therapy Product166,922,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductUrology29,790,000USD0001104659-26-058465
    Q1 2026Quarterly · 2026-03-31ProductWound Care39,402,000USD0001104659-26-058465
    FY 2025Yearly · 2025-12-31ProductDiabetes Product783,370,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductHome Respiratory Therapy Product433,050,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductOstomy212,838,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductProduct And Service Other288,192,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductSleep Therapy Product740,052,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductUrology116,022,000USD0001104659-26-018169
    FY 2025Yearly · 2025-12-31ProductWound Care188,508,000USD0001104659-26-018169
    Q3 2025Quarterly · 2025-09-30ProductDiabetes Product201,372,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductHome Respiratory Therapy Product107,256,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductOstomy53,274,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductProduct And Service Other72,586,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductSleep Therapy Product185,799,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductUrology28,976,000USD0001104659-25-104506
    Q3 2025Quarterly · 2025-09-30ProductWound Care48,001,000USD0001104659-25-104506
    Q2 2025Quarterly · 2025-06-30ProductDiabetes Product191,056,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductHome Respiratory Therapy Product109,526,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductOstomy51,893,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductProduct And Service Other72,302,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductSleep Therapy Product181,622,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductUrology28,696,000USD0001558370-25-011059
    Q2 2025Quarterly · 2025-06-30ProductWound Care46,822,000USD0001558370-25-011059
    Q1 2025Quarterly · 2025-03-31ProductDiabetes Product187,360,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductHome Respiratory Therapy Product108,606,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductOstomy49,499,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductProduct And Service Other71,771,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductSleep Therapy Product181,859,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductUrology28,143,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31ProductWound Care46,646,000USD0001104659-26-058465
    Q1 2025Quarterly · 2025-03-31GeographyInternational51,332,000USD0001558370-25-006964
    Q1 2025Quarterly · 2025-03-31GeographyUnited States2,580,716,000USD0001558370-25-006964
    Q1 2025Quarterly · 2025-03-31SegmentPatient Direct673,884,000USD0001558370-25-006964
    Q1 2025Quarterly · 2025-03-31SegmentProducts Healthcare Services1,958,164,000USD0001558370-25-006964
    FY 2024Yearly · 2024-12-31ProductDiabetes Product777,483,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductHome Respiratory Therapy Product435,954,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductOstomy195,923,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductProduct And Service Other268,274,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductSleep Therapy Product702,950,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductUrology107,121,000USD0001104659-26-018169
    FY 2024Yearly · 2024-12-31ProductWound Care192,407,000USD0001104659-26-018169
    Q4 2024Quarterly · 2024-12-31GeographyInternational59,219,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States2,636,853,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentPatient Direct695,022,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31SegmentProducts Healthcare Services2,001,050,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyInternational242,941,000USD0001558370-25-001940
    FY 2024Yearly · 2024-12-31GeographyUnited States10,457,942,000USD0001558370-25-001940
    FY 2024Yearly · 2024-12-31SegmentPatient Direct2,680,112,000USD0001558370-25-001940
    FY 2024Yearly · 2024-12-31SegmentProducts Healthcare Services8,020,771,000USD0001558370-25-001940
    Q3 2024Quarterly · 2024-09-30ProductDiabetes Product202,761,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductHome Respiratory Therapy Product108,968,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductOstomy50,555,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductProduct And Service Other68,186,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductSleep Therapy Product177,153,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductUrology27,748,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30ProductWound Care51,475,000USD0001104659-25-104506
    Q3 2024Quarterly · 2024-09-30GeographyInternational59,656,000USD0001558370-24-014255
    Q3 2024Quarterly · 2024-09-30GeographyUnited States2,661,469,000USD0001558370-24-014255
    Q3 2024Quarterly · 2024-09-30SegmentPatient Direct686,846,000USD0001558370-24-014255
    Q3 2024Quarterly · 2024-09-30SegmentProducts Healthcare Services2,034,279,000USD0001558370-24-014255
    Q2 2024Quarterly · 2024-06-30ProductDiabetes Product194,361,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductHome Respiratory Therapy Product109,687,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductOstomy47,059,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductProduct And Service Other66,256,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductSleep Therapy Product170,237,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductUrology25,645,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30ProductWound Care47,156,000USD0001558370-25-011059
    Q2 2024Quarterly · 2024-06-30GeographyInternational61,996,000USD0001558370-24-010720
    Q2 2024Quarterly · 2024-06-30GeographyUnited States2,609,010,000USD0001558370-24-010720
    Q2 2024Quarterly · 2024-06-30SegmentPatient Direct660,401,000USD0001558370-24-010720
    Q2 2024Quarterly · 2024-06-30SegmentProducts Healthcare Services2,010,605,000USD0001558370-24-010720
    Q1 2024Quarterly · 2024-03-31GeographyInternational62,070,000USD0001558370-25-006964
    Q1 2024Quarterly · 2024-03-31GeographyUnited States2,550,610,000USD0001558370-25-006964
    Q1 2024Quarterly · 2024-03-31SegmentPatient Direct637,843,000USD0001558370-25-006964
    Q1 2024Quarterly · 2024-03-31SegmentProducts Healthcare Services1,974,837,000USD0001558370-25-006964
    FY 2023Yearly · 2023-12-31ProductDiabetes Product723,318,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductHome Respiratory Therapy Product457,675,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductOstomy177,890,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductProduct And Service Other254,971,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductSleep Therapy Product669,784,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductUrology97,985,000USD0001104659-26-018169
    FY 2023Yearly · 2023-12-31ProductWound Care170,949,000USD0001104659-26-018169
    Q4 2023Quarterly · 2023-12-31GeographyInternational67,899,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31GeographyUnited States2,588,251,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentPatient Direct664,434,000USDLegacy provider
    Q4 2023Quarterly · 2023-12-31SegmentProducts Healthcare Services1,991,716,000USDLegacy provider
    FY 2023Yearly · 2023-12-31GeographyInternational275,292,000USD0001558370-25-001940
    FY 2023Yearly · 2023-12-31GeographyUnited States10,058,675,000USD0001558370-25-001940
    FY 2023Yearly · 2023-12-31SegmentPatient Direct2,552,572,000USD0001558370-25-001940
    FY 2023Yearly · 2023-12-31SegmentProducts Healthcare Services7,781,395,000USD0001558370-25-001940
    Q3 2023Quarterly · 2023-09-30GeographyInternational72,790,000USD0001558370-24-014255
    Q3 2023Quarterly · 2023-09-30GeographyUnited States2,518,952,000USD0001558370-24-014255
    Q3 2023Quarterly · 2023-09-30SegmentPatient Direct648,275,000USD0001558370-24-014255
    Q3 2023Quarterly · 2023-09-30SegmentProducts Healthcare Services1,943,467,000USD0001558370-24-014255
    Q2 2023Quarterly · 2023-06-30GeographyInternational64,690,000USD0001558370-24-010720

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.